CN101892302A - Detection method and kit of locus rs2336384 of susceptibility gene of hypertension - Google Patents
Detection method and kit of locus rs2336384 of susceptibility gene of hypertension Download PDFInfo
- Publication number
- CN101892302A CN101892302A CN 201010129037 CN201010129037A CN101892302A CN 101892302 A CN101892302 A CN 101892302A CN 201010129037 CN201010129037 CN 201010129037 CN 201010129037 A CN201010129037 A CN 201010129037A CN 101892302 A CN101892302 A CN 101892302A
- Authority
- CN
- China
- Prior art keywords
- gene
- site
- hypertension
- mfn2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 45
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 43
- 238000001514 detection method Methods 0.000 title claims abstract description 26
- 101150050341 Mfn2 gene Proteins 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000000523 sample Substances 0.000 claims description 17
- 230000003321 amplification Effects 0.000 claims description 12
- 230000001631 hypertensive effect Effects 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 10
- 208000007530 Essential hypertension Diseases 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 4
- 230000004927 fusion Effects 0.000 abstract description 4
- 108700025695 Suppressor Genes Proteins 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 206010020718 hyperplasia Diseases 0.000 abstract description 3
- 210000003470 mitochondria Anatomy 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 12
- 239000012634 fragment Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000015889 Mitofusin-2 Human genes 0.000 description 1
- 108050004120 Mitofusin-2 Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- NZCHHEFOTMKOJX-UHFFFAOYSA-K [6-[[3-carboxy-4-(3-oxido-6-oxoxanthen-9-yl)phenyl]carbamothioylamino]hexoxy-oxidophosphoryl] [5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound O1C(COP([O-])(=O)OP([O-])(=O)OCCCCCCNC(=S)NC=2C=C(C(=CC=2)C2=C3C=CC(=O)C=C3OC3=CC([O-])=CC=C32)C(O)=O)C(O)C(O)C1N1C=CC(=O)NC1=O NZCHHEFOTMKOJX-UHFFFAOYSA-K 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000011706 wistar kyoto rat Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the molecular biology and medicine field and relates to a method for detecting a susceptibility gene of hypertension and a detection kit thereof. The invention provides a method for detecting a susceptibility gene of essential hypertension, comprising the step of detecting the genetype of a mitochondrion fusion gene 2(Mfn2)/hyperplasia suppressor gene (HSG) locus rs2336384. The individual, rs2336384 of which carries the G genetype has obviously higher susceptibility of hypertension than the common people. The invention also discloses the corresponding detection kit which contains a primer amplifying the locus rs2336384 and a primer amplifying the region of the locus rs2336384 contained in the No.2 intron of the Mfn2 gene. Being used for detecting the genetype of the locus rs2336384, the method is simple and practicable, fast and efficient and low in cost and provides a simple and direct new way for hypertension diagnosis and treatment.
Description
Technical field
The present invention relates to molecular biology and medical field.More specifically, relate to human mitochondrion fusion gene 2 (Mfn2 gene) single nucleotide polymorphism (single nucleotide polymorphism, SNP) site rs2338384 and with the detection of essential hypertension dependency.The invention still further relates to the method and the test kit that detect this SNP site.
Background technology
(essential hypertension EH) is a kind of multifactor, multigenic disease to essential hypertension, by the common morbific common and multiple cardiovascular disorder of environment and heredity factor, human health has been caused great influence.Along with the development of molecular medicine, kind surplus the hypertension relative gene that has been found that has at present had 150, but the pathogenesis of EH still imperfectly understands, and hypertensive early diagnosis and proactive problem still fail to solve fully.EH is the coefficient result of gene and environment, and the variation 30%-60% of blood pressure is owing to heredity.Because environmental factors can be controlled and confirm, is changeless and hypertension genetic is learned factor.Therefore, control to variable factor, as prevention, can delay and prevent hypertensive morbidity to a certain extent, but the understanding deficiency of changeless inherited genetic factors is but being had a strong impact on to a certain extent to hypertension incidence, diagnosis and treatment the hypertension Hazard Factor.Therefore the research that hypertension genetic is learned very necessary (Wang Zuoguang, Wen Shaojun, Wu Zhaosu. hypertension, tumor susceptibility gene and single nucleotide polymorphism [J]. the hypertension magazine, 2001,9:259-264).
Nearly more than two decades comes, and about the research of hypertension therapeutic concentrates on more to the control of blood pressure with to the protection of target organ, and has obtained the development of advancing by leaps and bounds.But, these means are controlling blood pressure fundamentally, at present also seldom to the research of human endogenous hypertension gene, therefore, research endogenous hypertension mechanism is one of main direction of hypertension prevention and control research from now on, has important researching value and application prospect, if by regulating endogenous hypertension mechanism treatment essential hypertension, will promote the development of China's biologic medical technology, and be the huge medical expense of the annual saving of China.
The hypertension relative gene of being found is at present summed up and is got up may be summarized to be short shr gene and hypertension gene, and Mfn2 belongs to the latter.The predecessor of Mfn2 is intelligent [the Chen GH such as grade of Chinese scholar Chen Guang, Zhang CH, Zhu YQ, et al.Expression of a novel gene related to hypertension[J] .NatlMed J China, 1997,77:823-828.] in 1997 the spontaneous hypertensive rat (SHR) of cultivation and the vascular smooth muscle cell of normal Wistar Kyoto (WKY) rat are carried out the difference demonstration, clone a new gene---and hyperplasia suppressor gene (hyperplasia suppressor gene, HSG).It includes the base pair of 4160bp, 661 amino acid of encoding altogether (NM_014874, GeneBank Access U41803).After a series of bodies are interior, experiment in vitro is found [Chen KH, Guo XM, Dalong Ma, et al.Dysregulationof HSG triggers vascular proliferative disorders[J] .Nature Cell Biol, 2004,6,872-883.], HSG can suppress Ras-Raf albumen-Si significantly and split plain activated protein kinase genetic expression, and can activate the expression of antioncogene, check the propagation of cell cycle and inhibition various kinds of cell effectively, and this restraining effect realizes by apoptotic mode.Therefore the HSG gene is one of candidate gene of essential hypertension, after gene functional research shows, the HSG gene participates in plastosome and merges, therefore definite designation is that (mitofusin 2 for plastosome fusion gene 2, Mfn2) but at present less to the research of Mfn2 and EH, do not confirm the report of rs2336384 and EH dependency.
In sum, for the final treatment hypertension that realizes, this area presses for seeks the essential hypertension tumor susceptibility gene, and method, the test kit of exploitation detection essential hypertension tumor susceptibility gene, and relevant medicine.
Summary of the invention
The method and the detection kit that the purpose of this invention is to provide a kind of detection (comprising early diagnosis) hypertension susceptible gene.
The invention provides a kind of detection method of hypertension susceptibility gene, promptly detect the genotype in Mfn2 gene rs2338384 site, rs2338384 has the hypertensive onset risk of the genotypic individuality of G and is significantly higher than the general population.
Described rs2336384, the intron 2 (fragment contig contig:NT_021937.18 position 6583430T/G) that is arranged in Mfn2 wherein, thymus nucleic acid (DNA) sequence numbering: the rs2336384 position is based on SEQ ID NO:1/6; Primer 1 is based on SEQID NO:2/6; Primer 2 is based on SEQID NO:3/6; Probe 1 is based on SEQID NO:4/6; Probe 2 is based on SEQ ID NO:5/6; Amplified production is based on SEQ ID NO:6/6.
Particularly, the method comprising the steps of: (a) genomic dna of extracting sample, and amplification obtains Mfn2 gene intron 2; (b) genotype of mononucleotide polymorphism site rs2338384 in detection step (a) product.
The primer sequence of described amplification Mfn2 gene intron 2 is shown in SEQ ID NO 2 and SEQ ID NO 3.
The genotypic probe sequence of described detection rs2338384 is shown in SEQ ID NO 4 and SEQ ID NO 5.
Technology such as the order-checking that relates in the aforesaid method, amplification, extracting genomic dna all can adopt the routine operation method of this area.
The invention provides a kind of test kit that detects hypertension susceptible gene, it contains and site rs2338384 bonded probe.
In one embodiment of the invention, with the sequence of site rs2338384 bonded probe shown in SEQ IDNO:4 and SEQ ID NO:5.
The mentioned reagent box can also comprise the primer that comprises the zone in rs2338384 site in the specific amplification Mfn2 gene intron 2.
Comprise the sequence of primer in zone in rs2338384 site shown in SEQ ID NO:2 and SEQ ID NO:3 in one embodiment of the invention, with in the specific amplification Mfn2 gene intron 2.
The present invention shows after deliberation, proved that first Mfn2 gene mononucleotide polymorphism site rs2336384 (is arranged in Mfn2 intron 2, fragment contig contig:NT_021937.18 position 6583430T/G) closely related with hypertension, and found its new function: Mfn2 gene mononucleotide polymorphism site rs2336384 is positioned at Mfn2, (fragment contig contig:NT_021937.18 position 6583430T/G) genotypic change will cause hypertensive onset risk to raise in the intron 2, wherein the association study result shows, have significant difference (p＜0.05) in the distribution of Mfn2 gene rs2336384T → G in case and control group, this SNP polymorphism can change the transcription factor binding site point.Finished the present invention on this basis.
The invention provides a kind of method that the hypertension susceptibility of individuality is diagnosed, it comprises step: detect the genotype in this individual Mfn2 gene rs2336384 site, judge that with this this individuality suffers from hypertensive onset risk and whether be higher than the general population.
In a preference, described difference is the single nucleotide polymorphism that is selected from rs2336384.Rs2336384 is positioned at Mfn2, in the intron 2 (fragment contig contig:NT_021937.18 position 6583430T/G).Wherein, thymus nucleic acid (DNA) sequence numbering: the rs2336384 position is based on SEQID NO:1/6.
The invention provides the method whether a kind of test sample exists the single nucleotide polymorphism of Mfn2 gene, comprise step:
(a) with the genomic dna of Mfn2 gene intron 2 primer amplified samples, obtain amplified production; With
(b) genotype of mononucleotide polymorphism site rs2336384 in the detection amplified production.
The detailed sequence of Mfn2 gene can be the nucleotide sequence (can referring to network address http://www.ncbi.nlm.nih.gov/) of rs2336384 referring to accession number.
The inventor checks order to (fragment contig contig:NT_021937.18 position 6583430) zone in the intron in the Mfn2 gene 2.
The polymorphism in Mfn2 gene rs2336384 site can be directly used in hypertensive personalized treatment.When using the polymorphism in Mfn2 gene rs2336384 of the present invention site, also can use the hypertensive medicament of other treatment simultaneously.
The present invention also provides a kind of pharmaceutical composition, and it contains Mfn2 albumen of the present invention safely and effectively and pharmaceutically acceptable carrier or vehicle.This class carrier comprises (but being not limited to): salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.Pharmaceutical composition of the present invention can be made into the injection form, for example is prepared by ordinary method with the physiological saline or the aqueous solution that contains glucose and other assistant agents.Pharmaceutical composition such as tablet and capsule can be prepared by ordinary method.Pharmaceutical composition such as injection, solution, tablet and capsule are made under aseptic condition.The dosage of activeconstituents is the treatment significant quantity, for example every day 0.1 microgram/kg body weight-Yue 10 mg/kg body weight.In addition, polypeptide of the present invention also can use with the other treatment agent.
When making pharmaceutical composition, be that the Mfn2 albumen of safe and effective amount or its antagonist, agonist are applied to general Mammals, wherein this safe and effective dosage is usually at least about 0.1 microgram/kg body weight, and in most of the cases be no more than about 10 mg/kg body weight, preferably this dosage is about 0.1 microgram/kg body weight-Yue 100 mg/kg body weight.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.
The genotype that detects the rs2336384 of Mfn2 gene also can be used for diagnosing hypertension.Detection can be at genomic dna, also can be at the amplified fragments of Mfn2 gene.The genotype of the rs2336384 of Mfn2 gene can detect sudden change with existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization.
The invention provides a kind of method that detects the essential hypertension susceptible gene, it comprises the genotype in the rs2338384 site of detection line plastochondria fusion gene 2 (Mfn2), rs2338384 has the genotypic individuality of G, and hypertensive susceptibility is significantly higher than the general population.The invention also discloses the relevant detection test kit, this test kit contains the primer in amplification rs2338384 site, can also comprise the primer in No. 2 intron zone of amplification Mfn2 gene.Utilize the present invention to detect the genotype in rs2338384 site, method is simple, and is rapidly and efficiently with low cost, for hypertensive diagnosis and treatment provide a simple and direct new way.
Description of drawings
Fig. 1 is the detected result of MFn2 gene rs2338384 loci gene type.
Fig. 2 is the sequencing result sectional drawing.The genotypic sequencing result of a kind of SNP that has shown rs2338384.Rs2338384 is positioned at Mfn2, in the intron 2 (fragment contig contig:NT_021937.18 position 6583430T/G).
Embodiment
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning; Condition described in the laboratory manual (New York:ColdSpring Harbor Laboratory Press, 1989), or the condition of advising according to manufacturer.
Embodiment 1
Fluorescent PCR detects
One, experiment material
The 7900HT quantitative real time PCR Instrument is available from American AB I company, and pcr reaction solution (TaqManEXPress Master Mix) is synthetic by u.s.a. applied biosystem company (ABI) customization.
Two, primer and probe design and synthetic:
Partial sequence with MFn2 gene intron 1 is a template, uses Primer ExpressTM 2.0 software analysis TaqMan primer and probe site, and synthetic by u.s.a. applied biosystem company (ABI) customization.
Detect and use primer:
MFn2 gene rs2336384 upstream primer sequence: 5 '-CTCAGAGCTGTACTGTCTTTAAG-3 ' (SEQ ID NO 2)
MFn2 gene rs2336384 downstream primer sequence: 5 '-AGACAAGGGAAGGAAGTGAC-3 ' (SEQID NO 3)
Fluorescent probe:
MFn2 gene rs2336384 fluorescent probe 1:5 '-VIC-GCTGTGGCGTCATGCT-TAMRA-3 ' (SEQ ID NO 4)
MFn2 gene rs2336384 fluorescent probe 2:5 '-FAM-GCTGTGGCTTCATGCT-TAMRA-3 ' (SEQ ID NO 5)
Three, pattern detection:
Experiment detects 918 routine hypertension cases and 489 routine normal control crowds altogether, and every example is collected the about 2ml of blood sample sample, and with phenol/chloroform drawer genomic dna, the extracting result detects with micro-ultraviolet spectrophotometer (INFINIGEN company).
Carry out the fluorescent PCR amplification by following system, at last with SDS 2.3 scanning and cluster analyses.
| 384 orifice plates (ul) | |
| TaqMan?EXPress?Master?Mix(2X) | 2.5 |
| 20X?working?stock?of?SNP?Genotyping Assay | 0.25 |
| GDNA (about 3ng/ul) | 2.25 |
| The reaction cumulative volume | 5 |
| 1min@95℃ | 10sec@95℃ | 30sec@60℃ |
Four, type detected result:
The detected result of genome DNA extraction:
The genomic dna coincidence detection of all samples requires (260/280＞1.8, concentration＞10ng/ul, the detected result that No. 660, sample as shown below).
The detected result of MFn2 gene rs2336384 loci gene type
Embodiment 2
Detect the rs2336384 site of essential hypertension tumor susceptibility gene MFn2 gene with sequencing.Selecting each 10 example of above-mentioned hypertension case-control group sample checks order and judges the genotype of rs2336384.
One, experimental technique
The PCR sequencing primer still adopts above-mentioned fluorescent PCR primer, the directly order-checking of the purified back of the product of amplification.The instrument of order-checking is the 3130xl genetic analyzer of ABI company, analyzes with sequence analysis 5.2 analysis software, and the result also can check with chromas.
Two, experimental result
The sequencing result sectional drawing as shown in Figure 2.
As seen, the gene type assay result of the sequencing result of 20 examples and 7900 fluorescent PCRs is in full accord.
Three, the association analysis of MFn2 gene rs2336384 genotype and hypertension susceptible
The relatively employing RxC χ that MFn2 gene rs2336384 distributes in hypertensive patient and contrast
2The check. carry out statistical study with SPSS software, detected result and SPSS software analysis result as shown in the figure:
All documents of mentioning in the present invention are all quoted in this application and are done reference, are just quoted as a reference separately as each piece document.Should be understood that in addition read of the present invention above-mentioned tell about content after, those skilled in the art can make various changes or modification to the present invention, these forms fall within the application's appended claims institute restricted portion equally.
Sequence table
SEQUENCE?LISTING
＜110〉loyal hospital is pacified in the attached Beijing of the Capital University of Medical Sciences
Fudan University
＜120〉detection method and the detection kit in the rs2336384 site of hypertension susceptible gene
<130>1029
<160>6
<170>PatentIn?version?3.1
<210>1
<211>52
<212>DNA
<213>Homo?sapiens
<220>
<221>misc_feature
<222>(27)..(27)
<223>n＝g?or?t
<400>1
gagaaaacat?ctctcatagc?tgtggcntca?tgctgaggag?gaatgtagaa?ac 52
<210>2
<211>23
＜212〉dna sequence dna table
<213>Artificial
<400>2
ctcagagctg?tactgtcttt?aag 23
<210>3
<211>20
<212>DNA
<213>Artificial
<400>3
agacaaggga?aggaagtgac 20
<210>4
<211>16
<212>DNA
<213>Artificial
<400>4
gctgtggcgt?catgct 16
<210>5
<211>16
<212>DNA
<213>Artificial
<400>5
gctgtggctt?catgct 16
<210>6
<211>128
＜212〉dna sequence dna table
<213>Artificial
<400>6
ctcagagctg?tactgtcttt?aagccctgga?catatggctt?ccatgctgag?aaaacatctc 60
tcatagctgt?ggcgtcatgc?tgaggaggaa?tgtagaaacg?gaagtggggt?cacttccttc
120
ccttgtct 128
Claims (9)
1. the detection method in the rs2336384 site of a hypertension susceptible gene is characterized in that, detects the genotype in Mfn2 gene rs2338384 site, and described rs2338384 has the hypertensive onset risk of the genotypic individuality of G and is significantly higher than the general population.
2. detection method as claimed in claim 1 is characterized in that the rs2338384 site is positioned at Mfn2 gene intron 2.
3. detection method as claimed in claim 1 is characterized in that the method comprising the steps of:
(a) genomic dna of extracting sample, amplification obtains to comprise in the Mfn2 gene intron 2 zone in rs2338384 site;
(b) genotype of mononucleotide polymorphism site rs2338384 in detection step (a) product.
4. detection method as claimed in claim 3 is characterized in that, the primer sequence in zone that comprises the rs2338384 site in the amplification Mfn2 gene intron 2 is shown in SEQ ID NO 2 and SEQ ID NO 3.
5. detection method as claimed in claim 3 is characterized in that, the genotypic probe sequence that detects rs2338384 is shown in SEQ ID NO 4 and SEQ ID NO 5.
6. a test kit that detects hypertension susceptible gene is characterized in that, it contains and site rs2338384 bonded probe.
7. test kit as claimed in claim 6 is characterized in that, with the sequence of site rs2338384 bonded probe shown in SEQ ID NO:4 and SEQ ID NO:5.
8. test kit as claimed in claim 6 is characterized in that, it also comprises the primer that comprises the zone in rs2338384 site in the specific amplification Mfn2 gene intron 2.
9. test kit as claimed in claim 8 is characterized in that, the sequence of primer in zone that comprises the rs2338384 site in the specific amplification Mfn2 gene intron 2 is shown in SEQ ID NO:2 and SEQ ID NO:3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101290376A CN101892302B (en) | 2010-03-18 | 2010-03-18 | Use and detection kit of locus rs2336384 of susceptibility gene of hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101290376A CN101892302B (en) | 2010-03-18 | 2010-03-18 | Use and detection kit of locus rs2336384 of susceptibility gene of hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101892302A true CN101892302A (en) | 2010-11-24 |
| CN101892302B CN101892302B (en) | 2012-09-19 |
Family
ID=43101645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101290376A Expired - Fee Related CN101892302B (en) | 2010-03-18 | 2010-03-18 | Use and detection kit of locus rs2336384 of susceptibility gene of hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101892302B (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104099329A (en) * | 2013-04-02 | 2014-10-15 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility related gene locus and detection method thereof |
| CN104450884A (en) * | 2014-10-28 | 2015-03-25 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility relevant gene variation locus and detecting method thereof |
| CN104450689A (en) * | 2014-10-28 | 2015-03-25 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility relevant gene locus and detecting method thereof |
| CN104450688A (en) * | 2014-10-28 | 2015-03-25 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility relevant gene variation locus and detecting method thereof |
| CN104450690A (en) * | 2014-10-28 | 2015-03-25 | 首都医科大学附属北京安贞医院 | Primary hypertension susceptibility gene variation locus and detecting method thereof |
| CN105349634A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Gene variation locus related to hypertension susceptibility and detection method of gene variation locus |
| CN105349631A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | -2380 locus variant of mitochondrial fusion gene 2 and detection method thereof |
| CN105349630A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility gene locus rs11553681 and detection method thereof |
| CN105349632A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Gene variant of primary hypertension susceptibility gene Mfn2 and detection method thereof |
| CN105349639A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility gene locus rs61776496 and detection method thereof |
| CN105349636A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Primary hypertension susceptibility gene variation locus and detection method thereof |
| CN105349635A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | -2500 locus variant of mitochondrial fusion gene 2 and detection method of -2500 locus variant |
| CN105349633A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | -2459 locus variant of mitochondrial fusion gene 2 and detection method thereof |
| CN105349638A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | -2786 locus variant of mitochondrial fusion gene 2 and detection method of -2786 locus variant |
| CN105349629A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility gene locus rs11587948 and detection method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1876836A (en) * | 2006-04-27 | 2006-12-13 | 云南大学 | Kit for polymorphous detection of hypertension susceptible population by ADRB2 gene -654A/G |
| CN101033487A (en) * | 2006-03-07 | 2007-09-12 | 中国医学科学院阜外心血管病医院 | Method of detecting KLK1 gene rs5517 polymorphism correlated to primary hypertension |
| CN101103124A (en) * | 2004-11-19 | 2008-01-09 | Oy朱里拉布有限公司 | Method and kit for detecting a risk of essential arterial hypertension |
| CN101328502A (en) * | 2008-05-12 | 2008-12-24 | 中国医学科学院阜外心血管病医院 | Method and reagent box for predicting dihydrochlorothiazide antihypertensive efficacy |
| CN101343658A (en) * | 2007-09-30 | 2009-01-14 | 周宏灏 | Gene chip for detection of hyperpiesis individual medicine correlated gene mutation and uses thereof |
| CN101671723A (en) * | 2008-09-11 | 2010-03-17 | 上海市高血压研究所 | Haplotype consisting of single nucleotide polymorphism of kynureninase gene |
| CN201501881U (en) * | 2008-02-28 | 2010-06-09 | 夏珂 | Hypertension individuation pharmacotherapy genotype detecting chip and assorted reagent kit |
-
2010
- 2010-03-18 CN CN2010101290376A patent/CN101892302B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101103124A (en) * | 2004-11-19 | 2008-01-09 | Oy朱里拉布有限公司 | Method and kit for detecting a risk of essential arterial hypertension |
| CN101033487A (en) * | 2006-03-07 | 2007-09-12 | 中国医学科学院阜外心血管病医院 | Method of detecting KLK1 gene rs5517 polymorphism correlated to primary hypertension |
| CN1876836A (en) * | 2006-04-27 | 2006-12-13 | 云南大学 | Kit for polymorphous detection of hypertension susceptible population by ADRB2 gene -654A/G |
| CN101343658A (en) * | 2007-09-30 | 2009-01-14 | 周宏灏 | Gene chip for detection of hyperpiesis individual medicine correlated gene mutation and uses thereof |
| CN201501881U (en) * | 2008-02-28 | 2010-06-09 | 夏珂 | Hypertension individuation pharmacotherapy genotype detecting chip and assorted reagent kit |
| CN101328502A (en) * | 2008-05-12 | 2008-12-24 | 中国医学科学院阜外心血管病医院 | Method and reagent box for predicting dihydrochlorothiazide antihypertensive efficacy |
| CN101671723A (en) * | 2008-09-11 | 2010-03-17 | 上海市高血压研究所 | Haplotype consisting of single nucleotide polymorphism of kynureninase gene |
Non-Patent Citations (2)
| Title |
|---|
| 《Nature Genetics》 20081231 Yurii S Aulchenko等人 Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis 1402-1403 1-9 第40卷, 第12期 * |
| 《Nature Genetics》 20081231 Yurii S Aulchenko等人 Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis 1402-1403 1-9 第40卷, 第12期 2 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104099329A (en) * | 2013-04-02 | 2014-10-15 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility related gene locus and detection method thereof |
| CN104450884A (en) * | 2014-10-28 | 2015-03-25 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility relevant gene variation locus and detecting method thereof |
| CN104450689A (en) * | 2014-10-28 | 2015-03-25 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility relevant gene locus and detecting method thereof |
| CN104450688A (en) * | 2014-10-28 | 2015-03-25 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility relevant gene variation locus and detecting method thereof |
| CN104450690A (en) * | 2014-10-28 | 2015-03-25 | 首都医科大学附属北京安贞医院 | Primary hypertension susceptibility gene variation locus and detecting method thereof |
| CN105349634A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Gene variation locus related to hypertension susceptibility and detection method of gene variation locus |
| CN105349631A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | -2380 locus variant of mitochondrial fusion gene 2 and detection method thereof |
| CN105349630A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility gene locus rs11553681 and detection method thereof |
| CN105349632A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Gene variant of primary hypertension susceptibility gene Mfn2 and detection method thereof |
| CN105349639A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility gene locus rs61776496 and detection method thereof |
| CN105349636A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Primary hypertension susceptibility gene variation locus and detection method thereof |
| CN105349635A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | -2500 locus variant of mitochondrial fusion gene 2 and detection method of -2500 locus variant |
| CN105349633A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | -2459 locus variant of mitochondrial fusion gene 2 and detection method thereof |
| CN105349638A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | -2786 locus variant of mitochondrial fusion gene 2 and detection method of -2786 locus variant |
| CN105349629A (en) * | 2015-10-23 | 2016-02-24 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility gene locus rs11587948 and detection method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101892302B (en) | 2012-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101892302B (en) | Use and detection kit of locus rs2336384 of susceptibility gene of hypertension | |
| CN101892305B (en) | Method for detecting rs2295281 locus of hypertension susceptibility gene and detection kit | |
| CN101892311B (en) | Detection method and kit of single nucleotide polymorphism locus rs7550536 of susceptibility gene of hypertension | |
| CN102586408B (en) | The detection method of hypertension susceptible gene Mfn2 mononucleotide polymorphism site rs3820189 and detection kit | |
| Ryu et al. | − 759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment | |
| KR102053470B1 (en) | Methods and systems for pharmacogenomic treatment of cardiovascular conditions | |
| Pawlik et al. | Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone | |
| CN102808030B (en) | Application of single nucleotide polymorphism rs3888188 in detection of tuberculosis susceptibility | |
| CN104114714A (en) | Gabr-a2 diagnostic | |
| CN101886125B (en) | Method for detecting mononucleotide polymorphism locus rs2236058 of hypertension susceptibility genes and detection kit | |
| CN101886121B (en) | Method for detecting locus rs873457 of hypertension susceptibility genes and detection kit | |
| CN101892297B (en) | Detection method of single nucleotide polymorphism sites of hypertension susceptibility gene and kit thereof | |
| CN101892298B (en) | Method for detecting mononucleotide polymorphism rs2236055 locus of hypertension susceptibility gene and kit thereof | |
| CN101886129B (en) | Method for detecting mononucleotide polymorphism locus rs388915 of hypertension susceptibility genes AGTR 1 and detection kit | |
| CN101892296B (en) | Method for detecting hypertension susceptible gene and detection kit | |
| CN101892303B (en) | Method for detecting rs4846085 locus of hypertension susceptibility gene and detection kit thereof | |
| CN101979657B (en) | Method and kit for detecting rs2878677 locus of susceptibility gene of hypertension | |
| CN101892301B (en) | Method for detecting hypertension susceptibility gene and detection kit | |
| CN101805784B (en) | Single nucleotide polymorphism of human WNK4 genes and application thereof | |
| CN104099329A (en) | Hypertension susceptibility related gene locus and detection method thereof | |
| CN102732602A (en) | Method for detecting gene rs2255390 site of hypertension susceptible gene WNK1 and detection kit thereof | |
| CN104450688A (en) | Hypertension susceptibility relevant gene variation locus and detecting method thereof | |
| CN104450884A (en) | Hypertension susceptibility relevant gene variation locus and detecting method thereof | |
| CN104450690A (en) | Primary hypertension susceptibility gene variation locus and detecting method thereof | |
| CN105603053A (en) | High blood pressure susceptible gene SCN7A single nucleotide polymorphism site rs7565062 detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120919 Termination date: 20180318 |